Compare IDEXX Laboratories, Inc. (IDXX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Royal Bank of Canada — how do they compare? IDEXX Laboratories, Inc. trades at $519.51 (market cap $40.43B), while Royal Bank of Canada trades at $191.27 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 6.5× IDEXX Laboratories, Inc.'s market cap, and Royal Bank of Canada pays a 2.66% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Royal Bank of Canada for 47 Days on average.
| IDXX | RY | |
|---|---|---|
Market Cap | $40.43B | $262.99B |
Volume | 692,164 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $766.68 | $217.87 |
52-Week Low | $504.70 | $143.64 |
Typical Hold Time | 46 Days | 47 Days |
Enterprise Value | $41.32B | $730.11B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Royal Bank of Canada (RY) trades at $190.31, down 0.48% with a bearish technical signal despite strong fundamentals. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with a 32.01% net margin, while analyst consensus shows 43% buy ratings amid mixed sentiment.
RY presents a valuation disconnect with solid profitability (17.2% ROE) against bearish technicals. Investment opportunity lies in consistent earnings growth and dividend yield, though risks include stretched valuations and negative cash flow trends. The stock faces headwinds from technical indicators but maintains fundamental strength for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
